ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial British Journal of Cancer 109, 2096-2105 (15 October 2013)
Recruitment of TLR adapter TRIF to TLR4 signaling complex is mediated by the second helical region of TRIF TIR domain PNAS, vol. 110 no. 47: 19036–19041
FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer Cancer Res. 2013 Sep 1;73(17):5416-25
Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions.
Cancer Prevention Research, Jul 2013; 6: 666 - 674.
Luminex’s xMAP® Technology utilizes tiny color-coded beads in a patented liquid bead array format. The beads are dyed with 100 unique colors and each bead set can be coated with a specific reagent allowing the capture and detection of specific analytes from a sample. After capture and detection, the beads are read in the the Luminex analyzer. Lasers in the analyzer excite the internal dyes that identify each microsphere particle, and also the reporter dye captured during the assay. In this way, xMAP® Technology provides for multiplexing of up to 100 unique assays within a single sample.
Beads are dyed to create 100 distinct colors
Each bead color can be used for a different assay.
Bead array format allows for testing of up to 100 analytes from one sample
Multiple measurements for each assay
Assay results read in a compact flow analyzer.
Software reports results in real-time
Up to 9600 results in 1 hour
Quality results with significant cost and efficiency improvements